Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02461329
Other study ID # FN-Brno
Secondary ID
Status Not yet recruiting
Phase N/A
First received April 16, 2015
Last updated June 2, 2015
Start date May 2015
Est. completion date December 2016

Study information

Verified date June 2015
Source Brno University Hospital
Contact Milan Kratochvil, MD
Phone +420532232009
Email mkratochvil@fnbrno.cz
Is FDA regulated No
Health authority SUKL - State Institute for Drug Control:Czech Republic
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine whether volume therapy with a solution of gelatine has negative impact on coagulation, platelet function, renal function in comparison with crystaloid solution (Ringerfundin).


Description:

After obtaining the research ethics committee approval, 50 patients, undergoing elective surgery for hip replacement will be included. The informed consent must be signed prior to randomization. After arriving to the operation theatre, the patients informed consent and inclusion and exclusion criteria will be reviewed. Afterwards, the patients will be randomized in one of two groups. Prior to the anaesthesia induction, blood for the thrombocyte function test, coagulation tests and thrombelastometry wil be drawn via a metal cannula. A large bore peripheral venous cannula (G18 or more) will be introduced. In case of a ASA status of III and higher based on cardiovascular morbidity an arterial catheter via the radial artery for invasive blood pressure monitoring will be introduced. Urinary catheter will be introduced to monitor intraoperative diuresis. A continuous crystalloid infusion n a dose of 5 ml/kg/hour will be administered for basal fluid substitution. The volume replacement using blinded gelatine/crystalloid solution will be performed via fluid challenge (repeated 250 ml fluid boluses during a 5 minute interval) to hemodynamic targets (increase in blood pressure, decrease in heart rate), in case of a decrease of MAP to 65 mm Hg (16) or to 70 mmHg in preexisting hypertension. The hemodynamic variables before and after fluid challenge will be exactly recorded. In case the patient hemodynamics does dot respond to a fluid challenge, or in case of a drop of blood pressure to less than 55 mmHg, a bolus of 5-10 mg of ephedrine (repeatedly) will be administered. Further recorded variables will be: blood loss (suctioning, sponges), diuresis, number of transfusions administered. Repetitive hemoglobin concentration tests using the HemoCue 201+ device will be performed and an intraoperative blood transfusion trigger of 90 g/l of hemoglobin concentration will be used, 100 g/l in case of a patient with chronic cardiovascular or respiratory disease (5). After reaching the blood loss of 1000 ml, blood samples will be drawn for laboratory hemoglobin concentration and coagulation testing. The trigger for platelet transfusion will be a thrombocyte count of less than 50000 x 109, or sings of platelet dysfunction on thrombelastometry. Tranexamic acid will be administered in case of signs of fibrinolysis on thrombelastometry or in case of life threatening bleeding. At the end of surgery, a second blood sample for platelet function test, thrombelastometry, full blood count and standard coagulation tests will be drawn. The amount of blinded study infusion, continuous crystalloid solution, transfusions and ephedrine administered, diuresis and blood loss will be recorded. Blood urea and creatinine, diuresis, coagulations and full blood count will be recorded postoperatively. Hospital and ICU length of stay, hospital and 90-day mortality will be followed.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 2016
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender Both
Age group 19 Years to 85 Years
Eligibility Inclusion Criteria:

- patient scheduled for elective hip replacement surgery

- age between 19-85 years

- signed informed consent

Exclusion Criteria:

- informed consent not signed

- traumatic hip fracture

- anemia (hemoglobin level < 100 g/l)

- allergy to study drug and/or multiple allergies

- chronic heart failure with LVEF < 30%

- shock states

- coagulopathy

- thrombocytopenia

- thrombocytopathy

- chronic kidney disease with oliguria

- chronic antiplatelet drug medications

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Gelofusine® B. Braun
Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
Ringerfundin ® B. Braun
Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Kratochvil Milan, MD IBA - Masaryk University Institute of biostatistics and analyses

Outcome

Type Measure Description Time frame Safety issue
Other Perioperative complications Investigators will review all records after patient dismission and search for any complications related to medical care hospital stay, an expected average of 1 week Yes
Primary Change of coagulation status and platelet function Before and after the surgery (in OR) the investigator will obtain a blood sample from subject, standard coagulation test will be performed (INR, PT, aPTT, thrombin time), the investigator will perform ROTEM tests: EXTEM, INTEM and FIBTEM assay and blood sample will be tested for thrombocyte function - aggregation with ADP, collagen, epinephrine, TRAP - thrombin receptor-activated peptide. perioperative, an expected average of 2 hours Yes
Secondary Blood loss Amount of blood loss during the surgery and in the postoperative period perioperative, an expected average of 2 hours Yes
Secondary Renal function serum creatinine and blood urea nitrogen will be recorded 48 hours after surgery 2 days after surgery Yes
Secondary Transfusion needs Number of transfusion units administered during whole hospital stay hospital stay, an expected average of 1 week Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05077124 - Safe and Timely Antithrombotic Removal (STAR) Registry
Active, not recruiting NCT06114758 - Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
Recruiting NCT05900037 - GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery N/A
Completed NCT05397652 - The Aim of This Study is to Examine the Effect of Intravenously Administered Tranexamic Acid (TXA) on the Visual Clarity, Perioperative Hemorrhage, Duration and Early Postoperative Course of Shoulder Arthroscopy in Beach Chair Position. Phase 4
Not yet recruiting NCT06357455 - Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery N/A
Completed NCT06038981 - Assessment of the Impact of Perioperative Administration of Tranexamic Acid on Bleeding After Sleeve Gastrectomy N/A
Terminated NCT05093504 - Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D) N/A
Completed NCT05385952 - GATT-Patch Versus TachoSil in Liver Surgery N/A
Completed NCT04976530 - Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) N/A
Completed NCT04819945 - Clinical Safety and Performance of GATT-Patch in Open Liver Surgery N/A